SYNDAX PHARMACEUTICALS INC
NASDAQ: SNDX (Syndax Pharmaceuticals, Inc.)
Kemas kini terakhir: 2 jam lalu18.18
-0.64 (-3.40%)
| Penutupan Terdahulu | 18.82 |
| Jumlah Dagangan | 1,223,076 |
| Harga / Jualan (P/S) | 6.55 |
| Harga / Buku (P/B) | 111.30 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -416.67% |
| EPS Cair (TTM) | -3.85 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 160.71% |
| Nisbah Semasa (MRQ) | 5.80 |
| Aliran Tunai Operasi (OCF TTM) | -286.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -169.65 M |
| Pulangan Atas Aset (ROA TTM) | -36.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Syndax Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.29% |
| % Dimiliki oleh Institusi | 120.71% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |